Treatment burden and cost-effectiveness analysis of the neoadjuvant CROSS regimen in esophageal squamous cell carcinoma: a multicenter retrospective study

• DOI: 10.1093/dote/doad031
• Publication Date: 2023-05-27T01:43:22Z
• Authors: Xing Gao; Zhi-Hao Yang; Yi-Hsuan Cheng; Chun-Ling Chi; Tzu-Yi Yang; Kai-Hao Chuang; Chiao-En Wu; Joseph Jan-Baptis...; Yu-Wen Wen; Yin-Kai Chao
• Keywords: Regimen; Neoadjuvant Therapy

High-quality evidence indicated that both neoadjuvant carboplatin/paclitaxel (CROSS) and cisplatin/5-fluorouracil (PF) regimens in combination with radiotherapy improve survival outcomes compared to surgery alone patients esophageal cancer. It is not yet known whether they may differ terms of treatment burden healthcare costs. A total 232 Taiwanese squamous cell carcinoma who had undergone chemoradiotherapy (nCRT) either the CROSS (n = 153) or PF 79) were included. Hospital encounters adverse events assessed for determining burden. Cost-effectiveness analysis was undertaken using costs incurred over 3 years relation overall (OS) progression-free (PFS). Compared PF, regimen associated a lower burden: shorter inpatient days on average (4.65 ± 10.05 vs. 15.14 17.63 days; P < 0.001) fewer admission requirements (70% never admitted 20% group; 0.001). Patients group experienced significantly less nausea, vomiting, diarrhea. While benefits observed additional nCRT-related expenditures (1388 United States dollars [USD] added cost per patient), this remained cost-effective. At willingness-to-pay threshold 50,000 USD life-year, probability be more cost-effective than 94.1% PFS but decreased 68.9% OS. The use nCRT ESCC PF.